Printer Friendly

IMCERA'S BOARD OF DIRECTORS APPROVES $100 MILLION PROGRAM TO EXPAND MALLINCKRODT MEDICAL'S OPTIRAY PRODUCTION CAPACITY

      IMCERA'S BOARD OF DIRECTORS APPROVES $100 MILLION PROGRAM TO
       EXPAND MALLINCKRODT MEDICAL'S OPTIRAY PRODUCTION CAPACITY
    NORTHBROOK, Ill., Feb. 20 /PRNewswire/ -- The board of directors of IMCERA Group Inc. (NYSE: IMA) has approved a $100 million plan for the company's Mallinckrodt Medical unit of St. Louis to expand its production capability of Ioversol, known commercially as Optiray(R).
    The expansion results from the overwhelming success Optiray has achieved since its introduction by Mallinckrodt Medical in the U.S. in June 1989.  The nonionic, low-osmolality contrast agent is used by physicians for a wide range of diagnostic x-ray procedures to visualize and detect diseases in organs and the cardiovascular system.  Optiray offers improved safety and patient tolerance attributes compared to conventional contrast media products.
    It is the only new-generation x-ray contrast agent discovered, developed and marketed in the U.S.; it is now available in several international markets as well, including the United Kingdom, Germany and France.
    "Optiray has proven to be the most successful product in Mallinckrodt Medical's history," said C.R. Holman, Mallinckrodt Medical president and chief executive officer.  "This expansion reflects the enormous growth potential we anticipate as demand for the product increases in current markets and we continue to introduce it into new ones around the world.  Optiray, along with a number of other quality products marketed by Mallinckrodt Medical, has enabled the company to set its goal of $1 billion in net sales by 1995."
    A portion of the expansion project will involve increasing the production capabilities of the Ioversol plant currently located in St. Louis.  In addition, Mallinckrodt Medical is in advanced stages of discussion with Ireland's Industrial Development Authority on plans to build a new plant in that country.
    "Because of the warm reception Optiray has enjoyed overseas, we feel an Ioversol plant in Europe is critical to our ability to provide the product in a timely manner to that customer base," explained Holman.
    Mallinckrodt Medical is a worldwide leader in products for radiology, cardiology, critical care, nuclear medicine and anesthesiology.  It achieved net sales and operating earnings of $513 million and $87 million, respectively, in fiscal 1991.
    IMCERA, a Fortune 300 company with net sales of more than $1.6 billion in fiscal 1991, has two other international, technology-based businesses--Mallinckrodt Specialty Chemicals of Chesterfield, Mo., and Pitman-Moore of Lake Forest, Ill.
    -0-                   2/20/92
    /CONTACT:  Dave Prichard of IMCERA, 708-205-2270/
    (IMA) CO:  IMCERA Group Inc. ST:  Illinois, Missouri IN:  CHM SU: SM -- NY072 -- 1017 02/20/92 14:38 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 20, 1992
Words:417
Previous Article:WALTER C. MILLER NAMED EXECUTIVE PRODUCER-DIRECTOR OF THE ACADEMY OF TELEVISION ARTS & SCIENCES' '44TH ANNUAL PRIMETIME EMMY AWARDS'
Next Article:CHRYSLER CONFIRMS $862.5 MILLION PRIVATE ISSUE OF DEPOSITARY SHARES
Topics:


Related Articles
IMCERA'S MALLINCKRODT MEDICAL ANNOUNCES $15 MILLION EXPANSION AT RALEIGH, N.C., PLANT
MBI AND IMCERA'S MALLINCKRODT MEDICAL UNIT ANNOUNCE FILING OF NDS FOR ALBUNEX(R)
IMCERA REPORTS SIGNIFICANT INCREASE IN FISCAL 1993 FIRST QUARTER EARNINGS FROM CONTINUING OPERATIONS
IMCERA'S MALLINCKRODT MEDICAL UNIT AND SANDOZ PHARMA LTD. SIGN AGREEMENT TO SHARE MOLECULAR RESEARCH
IMCERA DISCUSSES REVIEW OF PITMAN-MOORE OPERATIONS; REVISES THIRD QUARTER AND FULL YEAR EPS EXPECTATIONS DUE TO PITMAN-MOORE PERFORMANCE
IMCERA'S BOARD OF DIRECTORS DECLARES QUARTERLY DIVIDENDS
MALLINCKRODT MEDICAL, OPTIMEDx FORM ALLIANCE TO DEVELOP AND DISTRIBUTE OPTICAL IMAGING AGENTS FOR CANCER CELL DETECTION
MALLINCKRODT INTRODUCES OPTIRAY(R) IN ULTRAJECT(R) SYRINGES IN JAPAN, WORLD'S SECOND LARGEST MEDICAL IMAGING MARKET
Mallinckrodt to Expand Hobart Facility
EPIX Medical and Mallinckrodt Announce Brand Name for MS-325

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters